Soricimed Eyes Phase I Trials in ‘12
With a new in-licensing deal signed and sealed, Sackville, N.B.-based biotech Soricimed Biopharma is preparing to begin its Phase I human tests for its own cancer drug and cancer diagnostic product in 2012.
On Wednesday, the company announced that it has in-licensed a proprietary peptide from the University Health Network of Toronto so it can commercialize the drug. A peptide is a small protein, and this particular peptide can stop growth in cervical, bone and lung cancer cells. It has similar properties to the peptide Soricimed has been developing for the past six years.
In an